These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 34352138)

  • 21. Effect of short-term treatment with gaboxadol on sleep maintenance and initiation in patients with primary insomnia.
    Deacon S; Staner L; Staner C; Legters A; Loft H; Lundahl J
    Sleep; 2007 Mar; 30(3):281-7. PubMed ID: 17425224
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Esmirtazapine in non-elderly adult patients with primary insomnia: efficacy and safety from a 2-week randomized outpatient trial.
    Ivgy-May N; Roth T; Ruwe F; Walsh J
    Sleep Med; 2015 Jul; 16(7):831-7. PubMed ID: 26047890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study.
    Murphy P; Moline M; Mayleben D; Rosenberg R; Zammit G; Pinner K; Dhadda S; Hong Q; Giorgi L; Satlin A
    J Clin Sleep Med; 2017 Nov; 13(11):1289-1299. PubMed ID: 29065953
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study.
    Uchiyama M; Kambe D; Imadera Y; Kajiyama Y; Ogo H; Uchimura N
    Psychopharmacology (Berl); 2022 Jul; 239(7):2143-2154. PubMed ID: 35296912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Zuranolone on Concurrent Anxiety and Insomnia Symptoms in Women With Postpartum Depression.
    Deligiannidis KM; Citrome L; Huang MY; Acaster S; Fridman M; Bonthapally V; Lasser R; Kanes SJ
    J Clin Psychiatry; 2023 Jan; 84(1):. PubMed ID: 36724109
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and safety of zolpidem-MR: a double-blind, placebo-controlled study in adults with primary insomnia.
    Roth T; Soubrane C; Titeux L; Walsh JK;
    Sleep Med; 2006 Aug; 7(5):397-406. PubMed ID: 16815744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial.
    Clayton AH; Lasser R; Parikh SV; Iosifescu DV; Jung J; Kotecha M; Forrestal F; Jonas J; Kanes SJ; Doherty J
    Am J Psychiatry; 2023 Sep; 180(9):676-684. PubMed ID: 37132201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel sublingual low-dose zolpidem tablet reduces latency to sleep onset following spontaneous middle-of-the-night awakening in insomnia in a randomized, double-blind, placebo-controlled, outpatient study.
    Roth T; Krystal A; Steinberg FJ; Singh NN; Moline M
    Sleep; 2013 Feb; 36(2):189-96. PubMed ID: 23372266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized placebo-controlled polysomnographic study of eszopiclone in Japanese patients with primary insomnia.
    Uchimura N; Kamijo A; Kuwahara H; Uchiyama M; Shimizu T; Chiba S; Inoue Y
    Sleep Med; 2012 Dec; 13(10):1247-53. PubMed ID: 23063301
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity.
    De Boer P; Drevets WC; Rofael H; van der Ark P; Kent JM; Kezic I; Parapatics S; Dorffner G; van Gerven J; Beneš H; Keicher C; Jahn H; Seiden DJ; Luthringer R
    J Psychopharmacol; 2018 Jun; 32(6):668-677. PubMed ID: 29848147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term efficacy and safety of zolpidem extended-release 12.5 mg, administered 3 to 7 nights per week for 24 weeks, in patients with chronic primary insomnia: a 6-month, randomized, double-blind, placebo-controlled, parallel-group, multicenter study.
    Krystal AD; Erman M; Zammit GK; Soubrane C; Roth T;
    Sleep; 2008 Jan; 31(1):79-90. PubMed ID: 18220081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia.
    Brooks S; Jacobs GE; de Boer P; Kent JM; Van Nueten L; van Amerongen G; Zuiker R; Kezic I; Luthringer R; van der Ark P; van Gerven JM; Drevets W
    J Psychopharmacol; 2019 Feb; 33(2):202-209. PubMed ID: 30644312
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical evaluation of the pharmacological impact of ashwagandha root extract on sleep in healthy volunteers and insomnia patients: A double-blind, randomized, parallel-group, placebo-controlled study.
    Langade D; Thakare V; Kanchi S; Kelgane S
    J Ethnopharmacol; 2021 Jan; 264():113276. PubMed ID: 32818573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia.
    Connor KM; Mahoney E; Jackson S; Hutzelmann J; Zhao X; Jia N; Snyder E; Snavely D; Michelson D; Roth T; Herring WJ
    Int J Neuropsychopharmacol; 2016 Aug; 19(8):. PubMed ID: 26979830
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of indiplon in older adults with primary insomnia.
    Walsh JK; Moscovitch A; Burke J; Farber R; Roth T
    Sleep Med; 2007 Nov; 8(7-8):753-9. PubMed ID: 17825616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of vestipitant, a neurokinin-1 receptor antagonist, in primary insomnia.
    Ratti E; Carpenter DJ; Zamuner S; Fernandes S; Squassante L; Danker-Hopfe H; Archer G; Robertson J; Alexander R; Trist DG; Merlo-Pich E
    Sleep; 2013 Dec; 36(12):1823-30. PubMed ID: 24293756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The orexin antagonist SB-649868 promotes and maintains sleep in men with primary insomnia.
    Bettica P; Squassante L; Zamuner S; Nucci G; Danker-Hopfe H; Ratti E
    Sleep; 2012 Aug; 35(8):1097-104. PubMed ID: 22851805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of the selective extrasynaptic GABA A agonist, gaboxadol, in a model of transient insomnia: a randomized, controlled clinical trial.
    Walsh JK; Mayleben D; Guico-Pabia C; Vandormael K; Martinez R; Deacon S
    Sleep Med; 2008 May; 9(4):393-402. PubMed ID: 17765013
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: two randomised controlled multicentre trials.
    Rajaratnam SM; Polymeropoulos MH; Fisher DM; Roth T; Scott C; Birznieks G; Klerman EB
    Lancet; 2009 Feb; 373(9662):482-91. PubMed ID: 19054552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness of ramelteon for insomnia symptoms in older adults with obstructive sleep apnea: a randomized placebo-controlled pilot study.
    Gooneratne NS; Gehrman P; Gurubhagavatula I; Al-Shehabi E; Marie E; Schwab R
    J Clin Sleep Med; 2010 Dec; 6(6):572-80. PubMed ID: 21206546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.